Fluid ORiented Therapy for yoUNg Asa 1patients
Not Applicable
Completed
- Conditions
- Hemodynamics
- Registration Number
- NCT03090399
- Brief Summary
In this retrospective analysis investigators will study the effects of using a minimally invasive hemodynamic monitoring (FloTrac-Edwards) on postoperative outcomes. Participants will compare a control group to a case group; in both groups ASA 1 patients suffering from advanced ovarian cancer underwent radical cytoreductive surgery. In case group hemodynamic was managed by using the FloTrac system; in the control group a standard hemodynamic monitoring was used.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
- ASA 1
Exclusion Criteria
- cardiac diseases
- pulmonary diseases
- renal diseases
- metabolic disorders
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method prevalence of complications up to 30 days
- Secondary Outcome Measures
Name Time Method days of hospitalization up to 12 weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie hemodynamic improvements with FloTrac in young ASA 1 patients?
How does goal-directed fluid therapy using FloTrac compare to standard monitoring in ovarian cancer surgery outcomes?
Are there specific biomarkers that predict optimal response to FloTrac-guided hemodynamic management in advanced ovarian cancer patients?
What adverse events are associated with FloTrac device use during intensive debulking procedures and how are they managed?
What combination therapies or alternative hemodynamic monitoring systems show promise for improving postoperative recovery in radical cytoreductive surgeries?